These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
    Author: Mazzola C, Guerrasio E.
    Journal: Am Heart J; 1988 Dec; 116(6 Pt 2):1797-801. PubMed ID: 2904753.
    Abstract:
    Doxazosin is a selective alpha 1-inhibitor for the reduction of calculated coronary heart disease (CHD) risk in hypertensive patients. Atenolol, although a widely used beta-blocker, appears to adversely affect blood lipids by increasing triglycerides and decreasing high-density lipoprotein (HDL) cholesterol. The aim of our study was to compare doxazosin and atenolol for their therapeutic efficacy in reducing CHD risk (decrease in blood pressure and effect on lipid distribution) and toleration. Patients with mild-to-moderate hypertension were randomized into two groups of 20 patients to receive once-daily atenolol (100 mg) or doxazosin (2 to 8 mg) for 8 weeks. Doxazosin was as effective as atenolol in reducing supine and standing blood pressure. Unlike atenolol, doxazosin did not produce a marked bradycardia. Doxazosin therapy produced favorable modifications in plasma lipid profiles by decreasing triglycerides and total cholesterol and by increasing HDL cholesterol and HDL/total cholesterol ratio. A reverse in this lipid profile was seen with atenolol. Therefore doxazosin may reduce calculated CHD risk more effectively than atenolol, based on the Framingham equation.
    [Abstract] [Full Text] [Related] [New Search]